Blood
Articles in this Issue
Phenotypic shift from primitive to monocytic immunophenotype is unique to patients treated with azacitidine + venetoclax (AZA/VEN) and associated with worse outcomes in AML
Abstract Background: Azacitidine (AZA) with Venetoclax (VEN) has improved outcomes in older or unfit patients with newly diagnosed acute myel...
Blinatumomab efficacy differs between newly diagnosed and relapsed/refractory B-ALL: Impact on MRD clearance and survival
Abstract Background Acute B-cell lymphoblastic leukemia (B-ALL) is an aggressive malignancy where minimal residual disease (MRD) negativity...
Trends and disparities in hematologic malignancy and sepsis-related mortality in adults aged ≥ 65 years in the United States from 1999 to2023: A CDC wonder database analysis
Abstract Introduction: Hematologic malignancy and sepsis are major contributors to mortality among the elderly population in the United Stat...
Propensity score matching analysis comparing the efficacy and treatment outcomes of belumosudil treatment with ruxolitinib therapy as second-line or beyond in chronic GVHD patients after steroid failure
Abstract Introduction Belumosudil (BEL), a selective Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, has been approved as 3rd line or...
Mesutoclax (ICP-248) monotherapy or combined with orelabrutinib demonstrates encouraging activity and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Abstract Introduction: BCL2 inhibition is an established CLL/SLL therapeutic strategy, and combination with Bruton tyrosine kinase inhibitio...
Can the development of drug-induced rash after mogamulizumab administration predict survival in mycosis fungoides/sezary syndrome? a trinetx-based analysis
Abstract Introduction Since the Food and Drug Administration approved the anti-CCR4 monoclonal antibody, mogamulizumab, for the treatment of...
Efficacy and safety of mitapivat in pediatric patients with pyruvate kinase deficiency who are not regularly transfused: Results from the Phase 3, global, randomized, double-blind, placebo-controlled ACTIVATE-Kids trial
Abstract Background: Pyruvate kinase (PK) deficiency is a rare chronic hemolytic anemia caused by homozygous or compound heterozygous mutati...
Transcriptomic analysis of CD34⁺ cells in myelofibrosis highlights their role in extracellular matrix dysregulation and marrow fibrosis
Abstract Myelofibrosis (MF) is the most aggressive Ph-negative myeloproliferative neoplasm, characterized by progressive bone marrow (BM) fi...
Lower risk of incident dementia in males but not females with TET2 clonal hematopoiesis - a secondary analysis of the aspriin in reducing events in the elderly (ASPREE) trial
Abstract Background Clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for many age-related diseases, includ...
Development of CD371 shielded hematopoietic stem cell grafts for protection against AML-directed immunotherapies
Abstract CAR T cells are a promising immunotherapy for AML. However, a major obstacle in the success of CAR T cells for AML has been that th...
Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola R+CHP) results in similar clinical outcomes than rituximab and dose adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R+DA-EPOCH) in patients with high-risk features diffuse large B-cell lymphoma (DLBCL): A single institution experience.
Abstract Background: DLBCL is the most prevalent aggressive form of B-cell lymphoma. Modern molecular profiling subdivides DLBCL into biologi...
The effect of chronic kidney disease on outcomes in patients admitted with acute promyelocytic leukemia not in remission: A nationwide analysis from 2016–2022
Abstract Background: Acute promyelocytic leukemia (APL) is a rare, aggressive subtype of acute myeloid leukemia with distinct molecular feat...
The use and safety of peripheral intravenous catheters (PIV) vs central venous catheters (CVC) for lymphoma patients receiving frontline anthracycline-based chemotherapy: A large multicenter real-world analysis (RWA)
Abstract Background: Given a potential risk of extravasation with vesicants and irritants, central venous catheters (CVCs), such as port-a-c...
Preliminary result of first-line orelabrutinib plus R-CHOP in CD5-positive diffuse large B-cell lymphoma (Rocket trial): A single-arm, phase II trial
Abstract Background: Primary CD5-positive diffuse large B cell lymphoma (DLBCL) accounts for approximately 5%-10% of newly diagnosed DLBCL ca...
Development of a high-yield cGMP lentiviral vector manufacturing process using suspension culture, a syenex lvv enhancer, and a closed aseptic system.
Abstract Background Lentiviral vectors (LVV) are widely used to genetically engineer T cells for cancer immunotherapies, including CAR-T and...
TIP-20: A novel FLT3 inhibitor with potent antileukemia activity
Abstract Mutations in the FLT3 gene represent one of the most common genetic alterations in acute myeloid leukemia (AML) and are associated...
Evaluating reverse transcriptase efficiency in CML: Consequences for deep molecular response classification and treatment-free remission decisions
Abstract Background In chronic myeloid leukemia (CML), deep molecular response (DMR) is defined as molecular response 4 (MR4) or deeper. If B...
Intratumoral cellular immunotherapy with autologous hyperactivated M1 SIRPα-low macrophages in non-Hodgkin lymphoma: Clinical results from a first-in-human Phase 1 study
Abstract Background. Many T cell Non-Hodgkin Lymphomas (NHL) lack an actionable target, and many B cell NHL show post-therapy antigen loss,...
Impact of systemic high-dose MTX and BTK inhibitors on outcomes in vitreoretinal lymphoma: A multicenter retrospective analysis
Abstract Background: Vitreoretinal lymphoma (VRL), a rare subtype of primary central nervous system lymphoma (PCNSL), poses significant ther...
Numerous clinically-detected asciminib-resistant BCR::ABL1 mutations disrupt allostery and confer cross-resistance to the novel clinically-active allosteric TKI tgrx-678
Abstract Objectives: Asciminib is a first-in-class potent and selective allosteric inhibitor of BCR::ABL1 that has demonstrated substantial...
A real-world analysis on the impact of GLP-1 receptor agonist use on all-cause mortality and hematological outcomes in AML/CML patients with obesity
Abstract Introduction: Obesity is a known risk factor for poor outcomes in acute and chronic myeloid leukemia (AML/CML), and this adverse ou...
Characteristics and clinical outcomes of ND-AML patients with bcor/bcorl1 mutations
Abstract 1.Background: Acute myeloid leukemia (AML) remains a challenging hematologic malignancy with heterogeneous gene...
A multinational study to explore patient preferences for chronic myeloid leukaemia treatments
Abstract INTRODUCTION: Tyrosine kinase inhibitors (TKIs) enable most patients with chronic phase chronic myeloid leukaemia (CP-CML) to achie...
A Phase 2 trial of AI-BEL (AZT/Interferon-α plus Belinostat) for HTLV-1 related adult T-cell leukemia-lymphoma: Final safety and efficacy Results
Abstract Background: HTLV-1 related adult T-cell leukemia-lymphoma (ATL) is generally fatal and incurable with modern drugs alone. Patients...
Comparative effectiveness of R-minichop versus R-CHOP in older patients with diffuse large B-cell lymphoma: A propensity score-matched analysis from a real-world grupo de estudio latinoamericano de linfoproliferativos (GELL) cohort
Abstract INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 30–40% of non-Hodgkin lymphomas in adults. In older...